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Background: Nebivolol has been shown to exhibit an effective cardioprotection through the nitric oxide pathway. In addition, it has been 
demonstrated that this third generation beta blocker presents prominent cardioprotective effects against chemotherapy-induced cardiotoxicity (CIC). 
We sought to evaluate the effect of prophylactic nebivolol use on prevention of CIC.
Methods: Forty-five consecutive patients with breast cancer and planned chemotheraphy were enrolled in the study. Twenty-seven patients were 
randomized to oral nebivolol and 18 were randomized to placebo. In the nebivolol group, nebivolol was given orally at a dose of 5mg/day. Left 
ventricle end-diastolic (LVDd) and end-systolic (LVSd) diameters, ejection fraction (EF) E/A and Ea/Aa ratio were measured at baseline and end of 
the chemotherapy protocol (at 6th month). B-type natriuretic peptide concentration (BNP) were measured in all patients.
Results: After 6 months, LV diameters increased in the placebo group (LVSd: 29.7 ± 3.4 mm to 33.4 ± 4.5 mm, p=0.01; LVDd: 47.2 ± 3.8 mm 
to 52.0 ± 4.6 mm, p=0.01). However, LVDd and LVDd remained unchanged in the nebivolol group (LVSd: 30.4 ± 3.5 to 31.0 ± 3.6, p=0.20; LVDd: 
47.0 ± 4.4 to 47.1 ± 4.0, p=0.93). The EF of the nebivolol group was similar at baseline and control echocardiography (p=0.12). However, the EF 
was significantly lower at control echocardiography in the control group (66.6 ± 5.5% vs. 57.5 ± 5.6%, p=0.01). At six-month, LVEF was lower in the 
placebo group than the nebivolol group (57.5 ± 5.6% vs. 63.8 ± 3.9%, p=0.01). E/A ratio and Ea/Aa ratio were higher in the nebivolol group than 
the control group at 6th month, (p=0.01). BNP levels was significantly increased in the nebivolol group (144 ± 66 vs. 204 ± 73, p=0.01).
Conclusions: This study shows that use of prophylactic nebivolol have cardioprotective effects in patients with CIC.
